What is DevaCell?
DevaCell is at the forefront of developing transformative therapeutic opportunities through its synthetic vector-based platform technology. The company's primary focus areas include oncology, gene therapy, and vaccines. Its lead program leverages novel synthetic vectors for oncolytic viral therapy, designed to bolster the immune system's capacity to identify and eliminate tumor cells. DevaCell's immunotherapeutics aim to activate multiple facets of the immune response, potentially leading to significant improvements in patient outcomes. The proprietary ONCoat technology is engineered to circumvent viral neutralization and facilitate repeat systemic delivery, positioning DevaCell as an innovator in the biopharmaceutical landscape.
How much funding has DevaCell raised?
DevaCell has raised a total of $65K across 1 funding round:
Debt
$65K
Debt (2021): $65K with participation from PPP
Key Investors in DevaCell
PPP
Public-Private Partnership
What's next for DevaCell?
With the recent influx of substantial expansion capital, DevaCell is poised for accelerated development and scaling of its innovative therapeutic platforms. The company's strategic focus on oncology, gene therapy, and vaccines, particularly its oncolytic viral therapy program, suggests a clear trajectory towards clinical advancement and market penetration. The significant Series B/C stage funding indicates investor confidence in DevaCell's technology and its potential to address unmet medical needs. Future endeavors will likely involve advancing its lead programs through further clinical trials, expanding its research and development capabilities, and potentially forging strategic partnerships to broaden its therapeutic reach and commercialization efforts.
See full DevaCell company page
